TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression
Journal of Neuro-Oncology · 2025-02 · 171 (3) · 637-649
DOI: 10.1007/s11060-024-04885-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 04.12.2024. Verfasst von David Wasilewski und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berl…. Hauptthemen laut MEDLINE: Brain Neoplasms, Thyroid Nuclear Factor 1, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Background
Thyroid Transcription Factor-1 (TTF-1) expression in lung adenocarcinoma (LUAD) has been studied for its prognostic value in early-stage and metastatic disease. Its role in brain metastasis remains unexplored. This study investigates the predictive value and association of TTF-1 status with clinicopathological variables in patients with synchronous LUAD brain metastases. Material and methods In this bicentric retrospective study, 245 patients with newly diagnosed, treatment-naïve brain metastasis undergoing resection were included. Patient data were retrieved from electronic records. Outcomes included overall and progression-free survival. Statistical analysis included Kaplan–Meier estimates and Cox proportional hazards regression.
Results
Mean Ki67 index in TTF-1 negative patients was 43% [95% CI 38–48%] compared to 32% [95% CI 29–35%] in TTF-1 positive (TTF-1 +) patients (p < 0.001). Tumor volume was significantly larger in TTF-1 negative (TTF-1-) patients (mean volume 24 mL [95% CI 18–31 mL]) vs. 15 mL [95% CI 12–17 mL] in TTF-1 + patients (padjust = 0.003). Perifocal edema was smaller in TTF-1- patients (mean volume: 58 mL [95% CI 45–70 mL]) vs. 84 mL [95% CI 73–94 mL] in TTF-1 + patients (padjust = 0.077). Tumor and edema volume did not correlate. TTF-1- patients showed worse overall, intracranial, and extracranial progression-free survival. In a multivariable Cox model, positive TTF-1 status was independently associated with improved outcomes. Negative TTF-1 status was associated with increased hazard for intracranial disease progression compared to extracranial progression.
Conclusion
In synchronous LUAD brain metastases, TTF-1 negativity reflects an aggressive phenotype with larger proliferation capacity and tumor volume. Future research should explore the underlying cellular and molecular alterations of this phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany. davidwasilewski2@gmail.com.
- Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany. davidwasilewski2@gmail.com.
- German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. davidwasilewski2@gmail.com.
- Department of Neurosurgery, University Regensburg Medical Center, Regensburg, Germany.
- Wilhelm-Sander Neuro-Oncology Unit, University Regensburg Medical Center, Regensburg, Germany.
- German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Förderung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Wasilewski, D., Araceli, T., Bischoff, P., Früh, A., Ates, R., Murad, S., Jung, N., Bukatz, J., Samman, M., Faust, K., Jünger, J., Witzenrath, M., Horst, D., Baborie, A., Koch, A., Capper, D., Heppner, F. L., Radbruch, H., Riemenschneider, M. J., …, & Frost, N. (2025). TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression. Journal of Neuro-Oncology, 171(3), 637-649. https://doi.org/10.1007/s11060-024-04885-y
Vancouver
Wasilewski D, Araceli T, Bischoff P, Früh A, Ates R, Murad S, et al. TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression. Journal of Neuro-Oncology. 2025;171(3):637-649. doi:10.1007/s11060-024-04885-y
BibTeX
@article{Wasilewski2025,
author = {Wasilewski, David and Araceli, Tommaso and Bischoff, Philip and Früh, Anton and Ates, Rober and Murad, Selin and Jung, Niklas and Bukatz, Jan and Samman, Majd and Faust, Katharina and Jünger, Julia and Witzenrath, Martin and Horst, David and Baborie, Atik and Koch, Arend and Capper, David and Heppner, Frank L and Radbruch, Helena and Riemenschneider, Markus J and Schmidt, Nils Ole and Vajkoczy, Peter and Proescholdt, Martin and Onken, Julia and Frost, Nikolaj},
title = {TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression},
journal = {Journal of Neuro-Oncology},
year = {2025},
volume = {171},
number = {3},
pages = {637--649},
doi = {10.1007/s11060-024-04885-y}
}
EUVIMED